About SEER

Founded: 2017
Employees: 124
CEO: Omid Farokhzad
WebsiteView website: seer.bio

Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Recent SEER News & Updates

Announcement • Jun 22

Seer And Korea University Present Preliminary Data Demonstrating Potential Of AI-Driven Plasma Proteomics For Multi-Cancer Screening

Seer, Inc. announced preliminary data presented at the 2026 American Society for Mass Spectrometry Annual Conference demonstrating the potential of the Proteograph Product Suite to enable AI-driven approaches for multi-cancer screening. The findings were presented by Sang-Won Lee, Ph.D., Professor at Korea University and Chief Executive Officer of TargetX, and Jaewoo Kang, Ph.D., Professor at Korea University and Chief Executive Officer of AIGEN Sciences, during the Seer Breakfast Symposium on June 1 in San Diego. By incorporating the Proteograph platform into plasma proteomics workflow, the researchers are able to profile the plasma proteome at remarkable depth and scale across thousands of patient samples with the reproducibility required for large-scale clinical research. The quality and consistency of the data enable exploration of new computational approaches that extend beyond conventional identification-based analyses. By combining deep proteomic datasets generated using the Proteograph and Orbitrap Astral mass spectrometer combined with an ID-Free AI framework, the researchers can learn directly from a substantially larger portion of the underlying data and uncover biological patterns that may otherwise remain inaccessible. The Proteograph platform significantly expands the breadth and depth of proteomic information captured from plasma samples. Applying self-supervised AI models directly to these rich datasets allows extraction of biological signal beyond what traditional workflows can utilize. At ASMS, results were presented from an ongoing collaboration between Seer and Korea University focused on generating one of the deep, unbiased plasma proteomics datasets assembled to date. The analysis included more than 5,500 plasma samples spanning ten major cancer types and healthy controls. The researchers reported deep and highly reproducible plasma proteome coverage at population scale, averaging more than 14,000 protein groups per sample, while enabling the construction of a comprehensive cohort-derived proteomic reference resource. An emerging ID-Free AI framework was described, designed to leverage the substantial portion of mass spectrometry data that remains uncharacterized by conventional identification-based workflows. These efforts establish a foundation for evaluating whether additional biological information contained within complex proteomic datasets can improve future multi-cancer screening strategies. The findings represent an early milestone in an ongoing collaboration between Seer and Korea University that is expected to analyze more than 20,000 clinical plasma samples across ten of Korea's highest-incidence cancer types.

Recent updates

No updates

Seer, Inc. Stock Price

SEER Share Price Performance

SEER Community Narratives

Proteograph Product Suite And Thermo Fisher Partnership Will Open Markets

Proteograph Product Suite And Thermo Fisher Partnership Will Open Markets

Trending Discussion

Recently Updated Narratives

SEER: Activist Bid And Buybacks Will Test Bullish Repricing Thesis

Snowflake Analysis

Seer, Inc. Key Details

About SEER

Recent SEER News & Updates

Seer And Korea University Present Preliminary Data Demonstrating Potential Of AI-Driven Plasma Proteomics For Multi-Cancer Screening

SEER: Activist Bid And Buybacks Will Test Bullish Repricing Thesis

SEER: Bullish Coverage And Activist Pressure Will Test Profitability Execution

Recent updates

Seer, Inc. Competitors

Whitehawk Therapeutics

Coherus Oncology

Canton Strategic Holdings

Protara Therapeutics